<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03386513</url>
  </required_header>
  <id_info>
    <org_study_id>IMGN632-0801</org_study_id>
    <nct_id>NCT03386513</nct_id>
  </id_info>
  <brief_title>Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN</brief_title>
  <official_title>A Phase 1/2, Multi-center, Open-label Study of IMGN632 Monotherapy Administered Intravenously in Patients With CD123-positive Acute Myeloid Leukemia and Other CD123-positive Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ImmunoGen, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ImmunoGen, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, multi-center, Phase 1/2 study to determine the MTD and assess the&#xD;
      safety, tolerability, PK, immunogenicity, and anti-leukemia activity of IMGN632 when&#xD;
      administered as monotherapy to patients with CD123+ disease.&#xD;
&#xD;
      The study is enrolling a pivotal cohort of frontline BPDCN patients and a cohort of&#xD;
      relapsed/refractory BPDCN patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study completed a dose escalation phase, and is now enrolling in a dose expansion phase&#xD;
      to further characterize the safety profile and to assess the efficacy of IMGN632 in patients&#xD;
      with BPDCN. IMGN632 is administered by IV on Day 1 of each cycle, with cycles repeating every&#xD;
      21 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2, 2018</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the rate of composite CR in BPDCN patients</measure>
    <time_frame>21-day cycle</time_frame>
    <description>CR+clinical CR [CRc]</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the duration of CR (DOCR) for patients with CR or CRc</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.03</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the rate of CR+CRc+CRh</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the duration of CR+CRc+CRh</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess ORR: CR+CRc+CRh+CRi+PR</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the duration of overall response</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess OS</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the percent of BPDCN patients able to bridge to stem cell transplant in the frontline and relapsed/refractory populations separately</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To characterize the PK of IMGN632, total antibody, and FGN849 (the active catabolite)</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the potential immunogenicity of IMGN632</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>ADA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess transfusion independence</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Conversion rate to independence of red blood cell (RBC) and platelet transfusion relative to baseline</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">252</enrollment>
  <condition>Blastic Plasmacytoid Dendritic Cell Neoplasm</condition>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Acute Lymphocytic Leukemia</condition>
  <condition>Myeloproliferative Neoplasm</condition>
  <arm_group>
    <arm_group_label>Escalation and Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escalation: IMGN632 was administered by IV on 2 different schedules for patients with relapsed/refractory AML or BPDCN.&#xD;
Expansion: the study is currently enrolling in 2 BPDCN expansion cohorts at the RP2D:&#xD;
Cohort 1: Relapsed or refractory BPDCN patients who have received 1-3 prior systemic therapies (incl. tagraxofusp-erzs and/or any other systemic therapy deemed appropriate for the treatment of BPDCN)&#xD;
Cohort 6: Pivotal cohort for frontline BPDCN patients who have not received prior systemic therapy. Patients may have received local therapy (radiotherapy, surgical excision, photodynamic therapy). Eligible patients must have a recurrence or progression in the field of local therapy OR disease outside the field of local therapy.&#xD;
Other expansion cohorts (not currently enrolling):&#xD;
• Cohort 2: Relapsed AML; Cohort 3: Relapsed or refractory ALL; Cohort 4: Other relapsed or refractory hematologic malignancies; Cohort 5: Relapsed or refractory AML at alternate dose or schedule</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IMGN632</intervention_name>
    <description>CD123-targeted ADC</description>
    <arm_group_label>Escalation and Expansion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Disease Characteristics:&#xD;
&#xD;
             a. Confirmation of CD123 positivity by flow cytometry or IHC. Patients who received&#xD;
             prior CD123-targeting agents will be allowed as long as the blasts still have&#xD;
             detectable CD123 expression.&#xD;
&#xD;
          2. Expansion inclusion:&#xD;
&#xD;
               -  Cohort 1 - Patients with relapsed or refractory BPDCN with 1-3 prior lines of&#xD;
                  therapy&#xD;
&#xD;
               -  Cohort 2 - Patients will have relapsed AML.&#xD;
&#xD;
               -  Cohort 3 - Patients will have relapsed or refractory ALL (including any subtypes:&#xD;
                  B-cell, T-cell, Ph+, and Ph-).&#xD;
&#xD;
               -  Cohort 4 - Patients will have relapsed or refractory &quot;other&quot; hematologic&#xD;
                  malignancies not included in the cohorts above (eg, high-risk/very high-risk MDS,&#xD;
                  MPN, CMML, BP- CML). Other CD123+ malignancies may be considered upon discussion&#xD;
                  with the Sponsor.&#xD;
&#xD;
               -  Cohort 5 - Patients will have relapsed or refractory (to non-intense therapies)&#xD;
                  AML.&#xD;
&#xD;
               -  Cohort 6 - Patients with frontline BPDCN who have not received prior systemic&#xD;
                  therapy.&#xD;
&#xD;
        Note: Patients in Cohort 6 may have received local therapy (radiotherapy, surgical&#xD;
        excision, photodynamic therapy). Eligible patients must have a recurrence or progression in&#xD;
        the field of local therapy OR disease outside the field of local therapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who, in the judgment of their treating physician, have appropriate standard&#xD;
             of care therapies will be excluded from Cohorts 1 through 5.&#xD;
&#xD;
          2. Frontline BPDCN patients with central nervous system (CNS) disease will be excluded. A&#xD;
             lumbar puncture must be performed during the 28-day screening period, prior to drug&#xD;
             administration. Relapsed or refractory BPDCN patients with a known history of CNS&#xD;
             disease must have been treated locally, have at least 1 lumbar puncture with no&#xD;
             evidence of CNS disease, and must be clinically stable prior to first dose. Concurrent&#xD;
             therapy for CNS prophylaxis or continuation of therapy for controlled CNS disease is&#xD;
             permitted with the approval of the Sponsor.&#xD;
&#xD;
          3. Patients with a history of veno-occlusive disease of the liver.&#xD;
&#xD;
          4. Patients with a history of Grade 4 capillary leak syndrome, or non-cardiac Grade 4&#xD;
             edema are ineligible, eg, related to tagraxofusp-erzs or other etiology.&#xD;
&#xD;
          5. Interval from prior cancer therapy: 1. For frontline BPDCN patients with prior local&#xD;
             therapy (eg, radiotherapy), patients must not have received treatment within 14 days&#xD;
             prior to drug administration on this study. 2. Relapsed or refractory BPDCN patients&#xD;
             must not have received any anti-cancer therapy including chemotherapy, immunotherapy,&#xD;
             radiotherapy, hormonal, biologic, or any investigational agents within 14 days prior&#xD;
             to drug administration on this study. Patients must have recovered to baseline from&#xD;
             all acute toxicity from this prior therapy.&#xD;
&#xD;
        Note: the exception that patients who have received a checkpoint inhibitor must not have&#xD;
        received that therapy within 28 days prior to drug administration on this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick Zweidler-McKay, MD</last_name>
    <role>Study Director</role>
    <affiliation>ImmunoGen, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ImmunoGen Clinical Trials</last_name>
    <phone>781-895-0600</phone>
    <email>medicalaffairs@immunogen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Banner Health MD Anderson Cancer Center</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jana Bergelin, MS</last_name>
      <phone>480-440-7458</phone>
      <email>BMDACCResearch@bannerhealth.com</email>
    </contact>
    <investigator>
      <last_name>Matthew Ulrickson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>City of Hope Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmed Aribi, MD</last_name>
      <phone>626-218-1133</phone>
      <email>aaribi@coh.org</email>
    </contact>
    <contact_backup>
      <phone>877-467-3411</phone>
    </contact_backup>
    <investigator>
      <last_name>Ahmed Aribi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Ternival</last_name>
      <phone>813-745-2629</phone>
      <email>christine.ternival@moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Kendra Sweet, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel DeAngelo, MD</last_name>
      <phone>617-632-2645</phone>
      <email>Daniel_DeAngelo@DFCI.HARVARD.EDU</email>
    </contact>
    <investigator>
      <last_name>Daniel DeAngelo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Halliwell</last_name>
      <phone>716-845-4971</phone>
      <email>Stephanie.Halliwell@RoswellPark.org</email>
    </contact>
    <contact_backup>
      <last_name>Eunice Wang, MD</last_name>
      <phone>716-845-3544</phone>
      <email>Eunice.Wang@RoswellPark.org</email>
    </contact_backup>
    <investigator>
      <last_name>Eunice Wang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke Cancer Institute</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Stowe, BSN, RN</last_name>
      <phone>919-681-4769</phone>
      <email>rachel.stowe@duke.edu</email>
    </contact>
    <contact_backup>
      <last_name>Susan Jones, BSN, RN</last_name>
      <phone>919-681-4769</phone>
      <email>susan.k.jones@duke.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Harry Erba, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor Scott &amp; White University Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Moshe Levy, MD</last_name>
      <phone>214-818-8472</phone>
    </contact>
    <investigator>
      <last_name>Moshe Y Levy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-7095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>713-794-4392</phone>
      <email>ndaver@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Naval Daver, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca White</last_name>
      <phone>206-667-5226</phone>
      <email>rlwhite@fredhutch.org</email>
    </contact>
    <contact_backup>
      <last_name>Kaysey Orlowski</last_name>
      <phone>206-667-1997</phone>
      <email>korlowsk@fredhutch.org</email>
    </contact_backup>
    <investigator>
      <last_name>Roland Walter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Recherche Clinique-Hématologie</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Delphine Lebon, MD</last_name>
      <phone>+33 3 22 45 59 14</phone>
      <email>lebon.delphine@chu-amiens.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Besancon, Hopital Jean Minjoz</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Deconinck, MD</last_name>
      <phone>+33381668232</phone>
      <email>eric.deconinck@univ-fcomte.fr</email>
    </contact>
    <investigator>
      <last_name>Eric Deconinck, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital St Antoine</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olliver Legrand, MD</last_name>
      <phone>+33 1 49 28 34 41</phone>
      <email>ollivier.legrand@sat.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Olliver Legrand, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori</name>
      <address>
        <city>Meldola</city>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Federica Frabetti</last_name>
      <email>federica.frabetti@irst.emr.it</email>
    </contact>
    <contact_backup>
      <last_name>Giovanni Martinelli, MD</last_name>
      <phone>+39 0543 739480</phone>
      <email>Giovanni.martinelli@irst.emr.it</email>
    </contact_backup>
    <investigator>
      <last_name>Giovanni Martinelli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto Europeo di Oncologia</name>
      <address>
        <city>Milano</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chiara Busacca</last_name>
      <phone>+39 02 94372 161</phone>
      <email>Chiara.Busacca@ieo.it</email>
    </contact>
    <contact_backup>
      <last_name>Maria Chiara Massaro</last_name>
      <phone>+39 02 57489 403</phone>
      <email>maria.massaro@ieo.it</email>
    </contact_backup>
    <investigator>
      <last_name>Corrado Tarella, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari I Politècnic La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pau Montsinos, MD</last_name>
      <phone>+34 96 1244925</phone>
      <email>montesinos_pau@gva.es</email>
    </contact>
    <contact_backup>
      <last_name>David Bossis</last_name>
      <phone>+34 961 244 864</phone>
      <email>pellicer_dav@gva.es</email>
    </contact_backup>
    <investigator>
      <last_name>Pau Montesinos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>December 21, 2017</study_first_submitted>
  <study_first_submitted_qc>December 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 29, 2017</study_first_posted>
  <last_update_submitted>July 9, 2021</last_update_submitted>
  <last_update_submitted_qc>July 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Antibody Drug Conjugate</keyword>
  <keyword>Other Hematologic Malignancies</keyword>
  <keyword>Myeloproliferative Neoplasms</keyword>
  <keyword>CD123</keyword>
  <keyword>MDS</keyword>
  <keyword>Relapsed, Refractory</keyword>
  <keyword>Acute Lymphocytic Leukaemia</keyword>
  <keyword>Blastic Plasmacytoid Dendritic Cell Neoplasm</keyword>
  <keyword>Acute Myeloid Leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

